SecBot SecBot
PRESS-RELEASE ·Filed Aug 26, 2026

BBIO

BridgeBio Pharma, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The study does not provide near-term revenue catalysts but strengthens the differentiation narrative for acoramidis versus competitors (e.g., tafamidis). Monitor ESC Congress 2026 for additional CMR data. Approval and market access for Attruby are already established; this study supports label expansion and long-term value creation.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$79.37
T+0 close · Aug 26, 2026 · via day close
Latest settled
−16.49%
T+20 · $66.28 · next T+60 in 2d
Vs SPY
−16.72%
α at T+20
Latest observation
+7.22%
T+55 · FF3 residual α
  1. T+0 · Aug 26 $79.37entry
  2. T+1 · 3mo ago −0.87%α −1.52% · $78.68
  3. T+5 · 3mo ago −3.62%α −3.50% · $76.50
  4. T+20 · 8w ago −16.49%α −16.72% · $66.28
  5. T+57 · todayOpen
  6. T+60 · in 2d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio announced first patient dosed in ASCEND-ATTR, a Phase 3b/4 study of acoramidis in ATTR-CM, designed to assess long-term effects on cardiac structure, function, and amyloid burden. This builds on encouraging CMR substudy data from the Phase 3 ATTRibute-CM trial suggesting potential disease reversal. The study is prospective and open-label, enrolling ~150 patients with annual imaging over 36 months.

Key Facts

  • First participant dosed in ASCEND-ATTR, a Phase 3b/4 open-label study of acoramidis in ATTR-CM
  • Study will enroll ~150 participants with annual CMR and echocardiography over 36 months
  • Primary endpoint: responder status at Month 36 by CMR based on improvement in LV systolic function
  • Acoramidis is the only oral, near-complete (≥90%) TTR stabilizer approved (Attruby) for ATTR-CM
  • Prior CMR substudy of ATTRibute-CM suggested improvement in LVMi, LVSVi, LVEF and evidence of amyloid regression
  • Additional data from ATTRibute-CM CMR substudy and OLE to be shared at ESC Congress 2026

Financial Impact

Phase 3b/4 study initiation, no financial impact disclosed; acoramidis is already approved and commercialized for ATTR-CM

Risk Factors

  • Single-arm, open-label design limits definitive conclusions versus placebo or active comparator
  • Enrollment and 36-month follow-up timeline reduces near-term impact
  • Risk that positive CMR substudy findings are not replicated in this larger, prospective study

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3351235

Track record

38 reports on BBIO

Performance horizon

10 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 14 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (14h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 26, 2026